Rigel partners alopecia areata candidates with Aclaris
Rigel Pharmaceuticals Inc. licensed Aclaris Therapeutics Inc. exclusive global rights to develop its preclinical Janus kinase (JAK) inhibitors for alopecia areata and additional dermatological diseases. The candidates are named ATI50001 and ATI50002.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.